Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;24 Suppl 2(0 2):S36-40.
doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5.

Clinical implications of molecular heterogeneity in triple negative breast cancer

Brian D Lehmann  1 , Jennifer A Pietenpol  2
Affiliations
Review

Clinical implications of molecular heterogeneity in triple negative breast cancer

Brian D Lehmann et al. Breast. 2015 Nov.

Abstract

Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials.

Keywords: Androgen receptor; Chemotherapy; Neoadjuvant; PIK3CA; TNBCtype.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: We have read and understood the International Committee of Medical Journal Editors (ICMJE) policy on declaration of interests and declare the following interests: BDL and JAP are inventors (PCT/US2012/065724) of intellectual property (TNBCtype) licensed by Insight Genetics Inc.

References

    1. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer. 2011;117:2747–53. - PMC - PubMed
    1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006;295:2492–502. - PubMed
    1. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81. - PubMed
    1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2007;13:4429–34. - PubMed
    1. Mieog JSD, van der Hage JA, van de Velde CJH. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007:CD005002. - PMC - PubMed

Publication types

Substances